AMPLUSFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD

Sanjay Sethi1
Edward Kerwin2
Henrik Watz3
Gary T Ferguson4
Robert M Mroz5,6
Rosa Segarra7
Eduard Molins7
Diana Jarreta7
Esther Garcia Gil7

1 Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, SUNY, Buffalo, NY, USA; 2 Clinical Research Institute, Medford, OR, USA; 3 Pulmonary Research Institute at LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany; 4 Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA; 5 Centrum Medycyny Oddychowej, Białystok, Poland; 6 Medical University of Białystok, Białystok, Poland; 7 AstraZeneca, Barcelona, Spain

**Background:** AMPLUSFY assessed the efficacy and safety of aclidinium bromide/formoterol fumarate (AB/FF) vs its monocomponents and tiotropium (TIO) in patients with moderate-to-very severe symptomatic COPD (NCT02796677).

**Methods:** In this 24-week, Phase III, double-dummy, active-controlled study, symptomatic patients (COPD Assessment Test score ≥ 10) were randomized to twice-daily AB/FF 400/12 µg, AB 400 µg, or FF 12 µg, or once-daily TIO 18 µg. Co-primary endpoints were change from baseline at week 24 in 1-hour morning post-dose FEV1 (AB/FF vs AB) and in pre-dose (trough) FEV1 (AB/FF vs FF). Non-inferiority of AB vs TIO in pre-dose FEV1 was also an objective. Normalized area under the curve (AUC)1,3,6 FEV1 and nighttime and early morning symptoms were also assessed. A subgroup participated in a 24-hour serial spirometry sub-study.

**Results:** A total of 1,594 patients were randomized; 566 entered the sub-study. At week 24, 1-hour post-dose FEV1 significantly improved with AB/FF vs AB, FF, and TIO (84, 84, and 10 mL; all P < 0.0001). AB/FF significantly improved trough FEV1 vs FF (55 mL, P < 0.001) and AB was non-inferior to TIO. AB/FF significantly improved AUC1,3,6 FEV1 vs all comparators (P < 0.0001) and provided significant improvements in early morning symptoms vs TIO. The 24-hour spirometry demonstrated significantly greater improvements with AB/FF in AUC12-24/24h vs all comparators, and in AUC9-24/24h vs FF or TIO at week 24.

**Conclusion:** In patients with moderate-to-very severe symptomatic COPD, twice-daily AB/FF significantly improved lung function vs monocomponents and TIO, and early morning symptom control vs TIO.

**Keywords:** aclidinium bromide, bronchodilators, LAMA, LABA, 24-hour lung function

**Introduction**

Combination therapy with a long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) is recommended by the Global initiative for chronic Obstructive Lung Disease as maintenance therapy for patients with stable COPD who experience persistent symptoms and/or a high risk of exacerbations.1

While the efficacy of the LAMA/LABA aclidinium bromide/formoterol fumarate (AB/FF) vs placebo and its monocomponents (AB and FF) has been previously reported,2,3 AMPLUSFY (NCT02796677) examined the effect of AB/FF compared with AB, FF, and tiotropium (TIO) on 24-hour lung function, health-related quality of life, and symptoms in a population of patients with moderate-to-very severe symptomatic COPD (COPD Assessment Test [CAT] score ≥ 10). As the efficacy of AB/FF, AB,
and FF vs placebo has been demonstrated previously, only active comparators were included in this study. In addition, a previous study has investigated AB vs TIO over 6 weeks, but AMPLIFY aimed to confirm the non-inferior bronchodilation of AB vs TIO over the longer term, and, for the first time, to provide a direct comparison of AB/FF vs TIO.

**Materials and methods**

AMPLIFY was a Phase III, 24-week, randomized, parallel-group, double-blind, double-dummy, active-controlled, multinational study of current or former smokers aged ≥40 years with stable, moderate-to-very severe symptomatic COPD (post-bronchodilator FEV₁/FVC <70% and post-bronchodilator FEV₁ <80% of predicted at screening, and a CAT score ≥10 at screening and randomization). Patients were randomized 2:3:2:3 to AB/FF 400/12 µg, AB 400 µg, or FF 12 µg twice daily via the Genuair™/Pressair® multidose dry powder inhaler (registered trademarks of AstraZeneca group of companies; for use within the USA as Pressair® and Genuair® within all other licensed territories), or TIO 18 µg once daily, via HandiHaler® (Figure 1). To maintain the double-blind, double-dummy nature of the study, all patients used both the Genuair/Pressair and the HandiHaler inhalers each morning, and the Genuair/Pressair inhaler only in the evening. Patients were excluded if they had a predominant asthma diagnosis, or a clinically significant respiratory condition other than COPD; had any respiratory tract infection or COPD exacerbation 6 weeks prior to/during screening; were hospitalized due to a COPD exacerbation in the previous 3 months; or were unable to maintain regular waking/sleeping cycles. Prohibited medications included: LABAs, LAMAs, short-acting β₂-agonists (except albuterol/salbutamol, which were permitted “as needed” throughout all study periods), short-acting muscarinic antagonists (except ipratropium, during wash-out and screening only), methylxanthines, leukotriene modifiers, phosphodiesterase-IV inhibitors, or non-selective β-blocking agents. During the washout and screening periods, patients were permitted to use ipratropium and albuterol/salbutamol. Patients were permitted to continue the following medication during screening, washout, and the treatment period provided administration was stable for ≥4 weeks: inhaled, oral, or parenteral corticosteroids (dose equivalent to ≤10 mg/day prednisone); oxygen therapy (<15 hours/day); or oral sustained-release theophylline, or selective β-blocking agents (eg, atenolol, metoprolol, nebivolol; stable administration for ≥2 weeks).

The study was conducted in 11 countries (Bulgaria, Czech Republic, Germany, Hungary, Israel, Poland, Russia, Spain, Ukraine, UK, and USA) between July 5, 2016 and June 8, 2017 in accordance with the International Conference on Harmonisation/Good Clinical Practice guidelines and the Declaration of Helsinki. The protocol was approved by the Institutional Review Boards/Independent Ethics Committees (Supplementary materials), and all patients gave written informed consent.

**Objectives and endpoints**

AMPLIFY had two objectives: to assess the bronchodilatory effect of AB/FF vs the monocomponents and to assess the non-inferiority of bronchodilation for AB vs TIO in change from baseline in trough FEV₁ at week 24.

For the AB/FF objective, the co-primary efficacy endpoints were changed from baseline in:

- 1-hour morning post-dose FEV₁ (AB/FF vs AB) at week 24.
- Morning pre-dose (trough) FEV₁ (AB/FF vs FF) at week 24.

**Figure 1** Study design.

**Abbreviations:** AB, aclidinium bromide; BID, twice daily; FF, formoterol fumarate; QD, once daily; TIO, tiotropium.
There were two secondary endpoints (both at 24 weeks):
- Change from baseline in normalized area under the curve (AUC) from 0 to 3 hours (AUC\textsubscript{0-3h}, FEV\textsubscript{1}) (AB/FF vs AB or FF).
- Proportion of St George’s Respiratory Questionnaire (SGRQ) total score responders (≥4-unit improvement, the minimal clinically important difference [MCID]).

Additional endpoints included change from baseline in FEV\textsubscript{1} over 3 hours post-dose on day 1 and week 24, including onset of action (post-dose FEV\textsubscript{1} at 5 and 15 minutes) on day 1; change from baseline in morning pre-dose (trough) FVC at weeks 1 and 24, and AUC\textsubscript{0-33h} FVC on day 1 and at week 24; change from baseline in SGRQ and CAT score, and proportion of CAT responders (≥2-unit improvement, the MCID)\textsuperscript{a} at week 24; rate of moderate and severe healthcare resource utilization exacerbations; and change from baseline over 24 weeks in nighttime and early-morning symptoms, (assessed using the validated Nighttime and Early-Morning Symptoms of COPD Instruments [NiSCI and EMSCI]).\textsuperscript{7,8} Evaluating-Respiratory Symptoms in COPD (E-RSTM\textsuperscript{TM}; COPD) total score,\textsuperscript{9} and rescue medication use.

A subset of patients participated in a 24-hour sub-study; serial spirometry was additionally performed between 4 and 24 hours on day 1 and at week 24. Change from baseline in FEV\textsubscript{1}, normalized AUC\textsubscript{0-12h}, AUC\textsubscript{12-24h}, AUC\textsubscript{0-24h}, FEV\textsubscript{1}, and FVC, overall nighttime and early morning symptom severity, and rescue medication were evaluated.

Treatment-emergent adverse events (TEAEs), serious adverse events (AEs), and major adverse cardiovascular events were recorded throughout the study.

All efficacy analyses, except exacerbations, were performed on the intent-to-treat (ITT) population (all randomized patients receiving ≥1 dose of study medication with baseline FEV\textsubscript{1} measurements). Non-inferiority analyses were performed on the per protocol population (patients in the ITT population meeting all inclusion/exclusion criteria, >70% treatment compliance, and no serious protocol deviations). Non-inferiority of AB vs TIO was defined as the lower bound of the two-sided 95% CI ≥−50 mL. Exacerbations and safety analyses were performed on the safety population (all randomized patients receiving ≥1 dose of study medication).

All lung function, health-related quality of life, and symptom measures were analyzed using a mixed model of repeated measures, responder analyses by logistic random-effect model, and exacerbation rates using a negative binomial regression model. Details are provided in Supplementary materials. To control for multiplicity, endpoints were tested in a pre-specified hierarchical sequence with the order: 1-hour post-dose FEV\textsubscript{1}, morning pre-dose (trough) FEV\textsubscript{1}, AUC\textsubscript{0-33h}, FEV\textsubscript{1}, SGRQ responder analysis.

### Results

Of 1,594 patients randomized, 1,583 were included in the ITT and safety populations, 1,403 in the per protocol population, and 1,356 (85.1%) remained on study treatment and completed the study (Figure 2). Baseline characteristics are presented in Table 1. A total of 566 patients were included in the sub-study (35.5%), of whom 563 were included in the sub-study ITT population and 493 (87.1%) remained on study treatment and completed the study. The baseline characteristics in the sub-study were similar to the total population (Table S1).

### Efficacy

At week 24, all active treatments improved 1-hour post-dose FEV\textsubscript{1} from baseline (Figure 3). Treatment with AB/FF resulted in significantly greater improvements in 1-hour post-dose FEV\textsubscript{1} compared with AB (84 mL, \(P<0.0001\); co-primary endpoint), FF (84 mL, \(P<0.0001\)), and TIO (92 mL, \(P<0.0001\)).

AB/FF led to significantly greater improvements in change from baseline in morning pre-dose (trough) FEV\textsubscript{1} vs FF (55 mL, \(P<0.001\); co-primary endpoint); however, the improvements for AB/FF compared with AB (14 mL) and TIO (19 mL) did not reach statistical significance (Figure 4).

For the AB vs TIO objective, AB was non-inferior to TIO in change from baseline in morning pre-dose (trough) FEV\textsubscript{1} at week 24 (least squares [LS] mean difference 7 mL [95% CI: −21 mL, 35 mL; \(P=0.6377\)]). All treatments improved post-dose FEV\textsubscript{1} over 3 hours on day 1 and at week 24, and the improvements observed with AB/FF were statistically significant compared with AB, FF, and TIO (Figure 5). On day 1 and at week 24, there were significantly greater improvements from baseline in AUC\textsubscript{0-33h} FEV\textsubscript{1} with AB/FF compared with AB, FF, or TIO (Figure 5). On day 1, all treatments improved post-dose FEV\textsubscript{1} from baseline at 5 minutes (143, 52, 122, and 49 mL, for AB/FF, AB, FF, and TIO, respectively) and 15 minutes (173, 101, 148, and 86, for AB/FF, AB, FF, and TIO, respectively). AB/FF treatment led to significantly greater improvements in post-dose FEV\textsubscript{1} compared with AB, FF, and TIO at both 5 minutes (91, 21, and 95 mL, respectively, all \(P<0.05\)) and 15 minutes (72, 25, and 87 mL, respectively, all \(P<0.01\)).

AB/FF improved trough FVC from baseline at week 1 (152 mL) and week 24 (116 mL). These improvements were
### Table 1 Baseline demographics and clinical characteristics (ITT population)

<table>
<thead>
<tr>
<th></th>
<th>AB/FF 400/12 µg (n=314)</th>
<th>AB 400 µg (n=475)</th>
<th>FF 12 µg (n=319)</th>
<th>TIO 18 µg (n=475)</th>
<th>Total (N=1,583)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mean age, years (SD)</strong></td>
<td>64.4 (8.5)</td>
<td>64.4 (8.1)</td>
<td>64.7 (8.3)</td>
<td>64.0 (8.6)</td>
<td>64.3 (8.4)</td>
</tr>
<tr>
<td><strong>Male, n (%)</strong></td>
<td>193 (61.5)</td>
<td>304 (64.0)</td>
<td>190 (59.6)</td>
<td>276 (58.1)</td>
<td>963 (60.8)</td>
</tr>
<tr>
<td><strong>Caucasian, n (%)</strong></td>
<td>297 (94.6)</td>
<td>444 (93.5)</td>
<td>303 (95.0)</td>
<td>457 (96.2)</td>
<td>1,501 (94.8)</td>
</tr>
<tr>
<td><strong>Current smoker, n (%)</strong></td>
<td>164 (52.2)</td>
<td>248 (52.2)</td>
<td>163 (51.1)</td>
<td>250 (52.6)</td>
<td>825 (52.1)</td>
</tr>
<tr>
<td><strong>Smoking history, mean pack-years (SD)</strong></td>
<td>46.2 (23.5)</td>
<td>45.4 (23.1)</td>
<td>45.2 (24.9)</td>
<td>46.4 (23.4)</td>
<td>45.8 (23.6)</td>
</tr>
<tr>
<td><strong>Concomitant ICS use, n (%)</strong></td>
<td>104 (33.1)</td>
<td>154 (32.4)</td>
<td>109 (34.2)</td>
<td>142 (29.9)</td>
<td>509 (32.2)</td>
</tr>
<tr>
<td><strong>COPD severity, n (%)</strong></td>
<td>Moderate: 165 (52.5)</td>
<td>231 (48.6)</td>
<td>148 (46.4)</td>
<td>258 (54.3)</td>
<td>802 (50.7)</td>
</tr>
<tr>
<td></td>
<td>Severe: 123 (39.2)</td>
<td>191 (40.2)</td>
<td>137 (42.9)</td>
<td>182 (38.3)</td>
<td>633 (40.0)</td>
</tr>
<tr>
<td></td>
<td>Very severe: 26 (8.3)</td>
<td>53 (11.2)</td>
<td>34 (10.7)</td>
<td>35 (7.4)</td>
<td>148 (9.3)</td>
</tr>
<tr>
<td><strong>Mean post-bronchodilator FEV&lt;sub&gt;1&lt;/sub&gt;, % predicted, mean (SD)</strong></td>
<td>50.9 (15.1)</td>
<td>49.6 (14.8)</td>
<td>49.6 (14.7)</td>
<td>51.2 (13.9)</td>
<td>50.3 (14.6)</td>
</tr>
<tr>
<td><strong>Bronchial reversibility, % (SD)</strong></td>
<td>15.3 (14.6)</td>
<td>15.9 (15.2)</td>
<td>14.6 (14.8)</td>
<td>15.0 (14.3)</td>
<td>15.2 (14.7)</td>
</tr>
<tr>
<td><strong>FEV&lt;sub&gt;1&lt;/sub&gt;, L, mean (SD)</strong></td>
<td>1.304 (0.519)</td>
<td>1.284 (0.506)</td>
<td>1.266 (0.514)</td>
<td>1.315 (0.503)</td>
<td>1.293 (0.509)</td>
</tr>
<tr>
<td><strong>FVC, L, mean (SD)</strong></td>
<td>2.672 (0.824)</td>
<td>2.670 (0.878)</td>
<td>2.629 (0.887)</td>
<td>2.692 (0.796)</td>
<td>2.669 (0.845)</td>
</tr>
<tr>
<td><strong>Mean exacerbations in previous 12 months (SD)</strong></td>
<td>0.4 (0.6)</td>
<td>0.4 (0.7)</td>
<td>0.4 (0.6)</td>
<td>0.3 (0.6)</td>
<td>0.4 (0.7)</td>
</tr>
<tr>
<td><strong>Mean SGRQ total score (SD)</strong></td>
<td>51.9 (16.4)</td>
<td>52.7 (17.1)</td>
<td>52.7 (16.6)</td>
<td>52.1 (16.7)</td>
<td>52.4 (16.7)</td>
</tr>
<tr>
<td><strong>Mean CAT score (SD)</strong></td>
<td>21.1 (6.0)</td>
<td>21.4 (6.4)</td>
<td>21.3 (6.2)</td>
<td>21.1 (5.9)</td>
<td>21.2 (6.1)</td>
</tr>
<tr>
<td><strong>Mean NiSci score (SD)</strong></td>
<td>1.07 (0.75)</td>
<td>1.09 (0.76)</td>
<td>1.09 (0.73)</td>
<td>1.09 (0.72)</td>
<td>1.09 (0.74)</td>
</tr>
<tr>
<td><strong>Mean EMSCI score (SD)</strong></td>
<td>1.37 (0.67)</td>
<td>1.36 (0.67)</td>
<td>1.37 (0.67)</td>
<td>1.40 (0.65)</td>
<td>1.38 (0.67)</td>
</tr>
<tr>
<td><strong>Mean E-RS score (SD)</strong></td>
<td>13.29 (6.11)</td>
<td>13.21 (6.37)</td>
<td>12.76 (6.11)</td>
<td>13.10 (6.16)</td>
<td>13.10 (6.20)</td>
</tr>
</tbody>
</table>

**Abbreviations:** AB, aclidinium bromide; CAT, COPD Assessment Test; EMSCI, Early Morning Symptoms of COPD Instrument; E-RS, Evaluating Respiratory Symptoms; FF, formoterol fumarate; ICS, inhaled corticosteroid; ITT, intent-to-treat; NiSci, Nighttime Symptoms of COPD Instrument; SGRQ, St George’s Respiratory Questionnaire; TIO, tiotropium.
score vs baseline by more than the MCID at week 24 (4.68, 4.95, and 5.58 units, respectively). FF improved SGRQ by 3.96 units compared with baseline. At week 24, all treatments improved CAT score vs baseline by more than the MCID (2.85, 2.54, 2.78, and 2.53 units for AB/FF, AB, FF, and TIO, respectively). There were no significant differences between treatments for SGRQ total score or CAT score, or in the proportion of SGRQ responders (48.1%, 49.1%, 49.6%, and 50.6% for AB/FF, AB, FF, and TIO, respectively) or CAT responders (58.8%, 59.5%, 57.8%, and 55.4% for AB/FF, AB, FF, and TIO, respectively).

The rate of moderate and severe exacerbations was similar between AB/FF, AB, and TIO (0.46, 0.48, and 0.41 exacerbations per patient per year, respectively) and lower than reported with FF (0.61).

Overall nighttime and overall early morning symptom severity scores showed numerical improvements with AB/FF compared with all treatments over 24 weeks, with significant improvements in overall early morning symptom severity score vs TIO (Figure 6). The change from baseline in E-RS total score over 24 weeks was similar between treatment groups (−1.73, −1.64, −1.25, and −1.38 units for AB/FF, AB, FF, and TIO, respectively).

At week 24, AB/FF significantly decreased the use of rescue medication vs TIO (−0.39 puffs/day, \( P<0.05 \)). Numerical reductions were seen with AB/FF compared with AB (−0.16 puffs/day, \( P=0.295 \)) and FF (−0.18 puffs/day, \( P=0.291 \)).

### 24-Hour serial spirometry sub-study

The sub-study demonstrated improvements from baseline in FEV\(_1\) with AB/FF vs monotherapies across the 24-hour post-dose period on day 1 and at week 24 (Figure 7). On day 1, AB/FF significantly improved FEV\(_1\) at all time points vs FF (except 15 minutes) and TIO (except 12 hours). At week 24, AB/FF significantly improved FEV\(_1\) at all time points vs FF. At week 24, AB/FF demonstrated significantly greater improvements vs all monotherapies in AUC\(_{0–24\text{h}}\) FEV\(_1\), and significant improvements in AUC\(_{0–12\text{h}}\) FEV\(_1\) vs FF, and in AUC\(_{0–24\text{h}/24\text{h}}\) FEV\(_1\) vs FF and TIO (Figure 8). AB/FF improved FVC across the 24-hour period (Figure S3); AB/FF improved AUC\(_{0–24\text{h}}\) FVC from baseline by 314 and 239 mL on day 1 and at week 24, respectively (Figure S3). Compared with all three monotherapies, AB/FF significantly improved AUC\(_{0–24\text{h}}\) FVC on day 1 and week 24, and AUC\(_{0–24\text{h}}\) FVC at week 24 (Figure S3).

Overall nighttime and overall early morning symptom severity score in the sub-study showed numerical improvements.
with AB/FF vs AB and TIO over 24 weeks. AB/FF demonstrated significant improvements in overall early morning symptom severity vs TIO (Figure 9).

At week 24 of the sub-study, all treatments decreased rescue medication use, and AB/FF significantly decreased the use of rescue medication vs AB, FF, and TIO (difference of −0.47, −0.67, and −0.58 puffs/day, respectively, all P<0.05).

**Safety**

The proportion of patients reporting TEAEs was similar between treatment groups, as was incidence of the most common events (COPD exacerbation, nasopharyngitis, and headache; Table 2). The incidence of serious AEs, major adverse cardiovascular events, and AEs leading to discontinuation or death was low and similar across treatment groups (Table 2).
Figure 7 Change from baseline in FEV\textsubscript{1} over 24 hours post-dose (A) on day 1 and (B) at week 24, sub-study ITT population.

Notes: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 for AB/FF vs all other treatments. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 for AB/FF vs FF and TIO. **P < 0.01; ***P < 0.001 for AB/FF vs AB and TIO. **P < 0.01; ***P < 0.001 for AB/FF vs FF. Data are least squares means ± standard error.

Abbreviations: AB, aclidinium bromide; FF, formoterol fumarate; ITT, intent-to-treat; TIO, tiotropium bromide.

Figure 8 Change from baseline in normalized (A) AUC\textsubscript{0–12/12 h}, (B) AUC\textsubscript{12–24/12 h} and (C) AUC\textsubscript{0–24/24 h} FEV\textsubscript{1} at week 24, sub-study ITT population.

Notes: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Data are least squares means ± standard error.

Abbreviations: AB, aclidinium bromide; AUC, area under the curve; FF, formoterol fumarate; ITT, intent-to-treat; TIO, tiotropium bromide.
Discussion

In this 24-week, Phase III, active-controlled study in patients with moderate-to-very severe symptomatic COPD, treatment with AB/FF 400/12 µg led to rapid improvements in lung function vs monocomponents and TIO that were sustained over 24 hours and reduced overall early morning COPD symptoms vs TIO. The lung function improvements observed in this study were within the range of those reported in previous studies of AB/FF vs monocomponents,2,3,10,11 and the improvements from baseline in 1-hour post-dose FEV1 reported for AB/FF vs AB confirm the contribution of FF to the efficacy of AB/FF. Although this study was not intended to investigate hyperinflation, the post-dose FVC results indicate that AB/FF increased the overall vital capacity of the lung vs monocomponents and TIO.

This was the first study to report the efficacy of AB/FF vs TIO; a previous study of AB demonstrated similar lung function efficacy compared with TIO over 6 weeks,4 and the present study confirmed that AB is statistically non-inferior to TIO over a longer treatment period. This was also the first study to report improvements in AUC0–3/3 h and 24-hour bronchodilation for AB/FF vs both the monocomponents and TIO.

In the sub-study, AB/FF demonstrated increased 24-hour bronchodilation vs comparators with the greatest benefits observed in the first few hours following administration and in the 12–24-hour post-dose period, during nighttime and early morning hours. Interestingly, the attenuated FEV1 response following evening administration, compared with the morning response seen for all three twice-daily treatments...

Table 2 Incidence of treatment-emergent adverse events (safety population)

<table>
<thead>
<tr>
<th></th>
<th>AB/FF 400/12 µg (n=314)</th>
<th>AB 400 µg (n=475)</th>
<th>FF 12 µg (n=319)</th>
<th>TIO 18 µg (n=475)</th>
<th>Total (N=1,583)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any AE, n (%)</td>
<td>183 (58.3)</td>
<td>289 (60.8)</td>
<td>210 (65.8)</td>
<td>285 (60.0)</td>
<td>967 (61.1)</td>
</tr>
<tr>
<td>SAE, n (%)</td>
<td>23 (7.3)</td>
<td>41 (8.6)</td>
<td>22 (6.9)</td>
<td>37 (7.8)</td>
<td>123 (7.8)</td>
</tr>
<tr>
<td>MACE, n (%)</td>
<td>2 (0.6)</td>
<td>2 (0.4)</td>
<td>4 (1.3)</td>
<td>3 (0.6)</td>
<td>11 (0.7)</td>
</tr>
<tr>
<td>AE leading to discontinuation, n (%)</td>
<td>17 (5.4)</td>
<td>37 (7.8)</td>
<td>27 (8.5)</td>
<td>32 (6.7)</td>
<td>113 (7.1)</td>
</tr>
<tr>
<td>AE leading to death, n (%)</td>
<td>1 (0.3)</td>
<td>1 (0.2)</td>
<td>4 (1.3)</td>
<td>2 (0.4)</td>
<td>8 (0.5)</td>
</tr>
</tbody>
</table>

Most common TEAEs (≥5% of patients in any treatment group)

- COPD exacerbation, n (%) 56 (17.8) 90 (19.0) 68 (21.3) 75 (15.8) 289 (18.3)
- Nasopharyngitis, n (%) 36 (11.5) 47 (9.9) 39 (12.2) 64 (13.5) 186 (11.8)
- Headache, n (%) 16 (5.1) 19 (4.0) 17 (5.3) 25 (5.3) 77 (4.9)

Abbreviations: AB, aclidinium bromide; AE, adverse event; FF, formoterol fumarate; MACE, major adverse cardiovascular event; SAE, serious AE; TEAE, treatment-emergent AE; TIO, tiotropium.
(AB/FF, AB, and FF), has been observed previously and can potentially be explained by the natural diurnal changes in lung function that have been reported in patients with COPD. Although the link between lung function and time of day is not well characterized, particularly given the heterogeneous nature of COPD, 24-hour spirometry has shown circadian variation in FEV₁, with the highest values reported mid-morning, a steady decline throughout the day, and the lowest values in the early hours of the morning. Therefore, twice-daily bronchodilators, such as AB/FF or AB, may be beneficial in counteracting this characteristic dip in airflow during the evening and at nighttime.

For patients receiving AB/FF, significant improvements were observed in overall early morning symptoms vs TIO in the sub-study and total population. Numerical improvements were observed in overall nighttime and early morning symptoms for AB/FF vs all monotherapies in the sub-study and total population, except for nighttime symptoms vs FF in the sub-study population. The magnitude of the improvements observed in both the nighttime and early morning symptom scores with AB/FF was similar to those seen previously. The lung function improvements observed with AB/FF 12–24 hours post-dose illustrate the beneficial effects of dual bronchodilation over monotherapy, but together with the improvements in symptom scores, also suggest the potential benefits of twice-daily administration of dual bronchodilators for some patients.

The proportion of patients achieving clinically important improvements in patient-reported health-related quality of life outcomes was similar across all treatment groups. Nearly half the patients in this study reported clinically significant improvements in SGRQ, which is in line with previous studies, and nearly 60% reported clinically relevant improvements in CAT. The improvements in CAT score observed are consistent with those reported in a previous 24-week study of AB/FF vs salmeterol/fluticasone 50/500 µg. This is noteworthy, as both studies enrolled symptomatic patients with baseline CAT scores of ≥20 units, so improvements in health status could be of particular significance for this group of patients. It was unexpected that although they achieved the MCID, the improvements in SGRQ were smaller than previously reported, and AB/FF did not provide significantly greater improvements in SGRQ total score or responder rates vs monotherapies or TIO. Recent improvements in the standard of COPD patient care and effective modern bronchodilator therapy might mean that it is more difficult to achieve large changes in the SGRQ total score, particularly in a patient population with more severe COPD than previous studies. In addition, patient-reported outcome measures give useful insight into how a patient perceives their treatment is progressing, but are, by definition, subjective. As a result, patient-reported outcomes may lack the sensitivity to detect more subtle improvements between active treatments.

When considering possible limitations of this study, it should be noted that the population was not enriched for patients who experienced frequent exacerbations. Exacerbation rates were similar between patients receiving AB/FF, AB, and TIO and were in line with similar studies in patients with moderate-to-severe COPD, where AB/FF demonstrated significant improvements vs placebo in the pooled analysis of the pivotal studies. A longer duration study in a population of exacerbation-prone patients may further elucidate any potential differences for AB/FF compared with monotherapy.

With regard to the strength of the symptom score instruments, Mocarski et al and Hareendran et al showed good internal consistency, reliability, and test–retest reliability for the NiSCI and EMSCI scores, and moderate-to-strong correlations with the SGRQ scores and E-RS total score. Further validation and increasing adoption of the early morning and nighttime COPD symptom instruments would help to strengthen the results of this study.

One of the strengths of this study, however, lies in the selection of a symptomatic population with more severe COPD; patients were required to have a CAT score of ≥10 (mean baseline CAT score: 21.2), and, unlike other AB/FF studies, this study had no lower limit to FEV₁, which resulted in a population with more severe and more symptomatic patients than previous studies. Another area of this study that should be considered a strength was the inclusion of the 24-hour serial spirometry sub-study, which coupled with the nighttime and early morning symptom score data allowed evaluation of effects of AB/FF on lung function and symptoms simultaneously over the 24-hour period.

Additional studies of twice-daily AB/FF compared with twice-daily AB, and FF, and once-daily TIO over the longer term and/or in specific sub-groups of patients, would further support the encouraging findings of this study. It would be interesting, for example, to look at AB/FF treatment in patients who specifically report higher levels of nighttime symptoms, and who may derive additional benefit from the twice-daily dosing of AB/FF. Furthermore, as AB/FF has previously demonstrated improvements in physical activity compared with placebo within the suggested MCID range for physical activity, additional studies with standardized
exercise tests or activity measurement could confirm whether the increased daytime and evening bronchodilation reported for AB/FF vs once-daily bronchodilator monotherapy may also provide improved activity tolerance for patients with COPD.

**Conclusion**

In conclusion, twice-daily AB/FF 400/12 µg treatment demonstrated significantly greater bronchodilation in patients with moderate-to-very severe symptomatic COPD compared with monocomponents and TIO at 24 weeks. AB monotherapy demonstrated non-inferiority to TIO in trough FEV$^1$, and all treatments in this study improved health-related quality of life outcomes at week 24. The 24-hour serial spirometry sub-study demonstrated that the most significant lung function benefits over monotherapies were observed in the 12–24-hour post-dose period, which coincided with significant improvements in overall early-morning symptom severity score compared with TIO. Overall, the findings of AMPLIFY support the sustained efficacy of AB/FF over 24 hours and indicate that AB/FF 400/12 µg may provide improved nighttime and early morning symptom control, compared with monotherapies.

**Data availability**

Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

The protocol and the statistical analysis plan can be found at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=22775.

**Acknowledgments**

The authors would like to thank the patients, investigators, and site staff involved in the study. The authors would also like to thank Ferran Chuecos for his role in statistical programming, Alejandra Lei, Ana Frances, and Marta Pujol for their role in providing medical safety monitoring and for input on the definition and interpretation of the safety analyses, and Joaquim Delgadillo, a former employee of AstraZeneca, for his contribution to the study design.

Medical writing support, under the direction of the authors, was provided by Siobhán Hoy of CMC CONNECT, a division of McCann Health Medical Communications Ltd, Glasgow, UK, funded by AstraZeneca, Cambridge, UK, in accordance with Good Publication Practice (GPP3) guidelines.17

Data of this manuscript have previously been presented at the 2018 meeting of the American Thoracic Society, the 2018 meeting of the European Respiratory Society, the 2018 Aspen Lung Conference, and the 2018 Eastern Pulmonary Conference (Am J Respir Crit Care Med 2018;197:A4235; Am J Respir Crit Care Med 2018;197:A4241).

This study was funded by AstraZeneca with support from Circassia. The sponsor did not place any restriction on authors about the statements made in the final article.

**Author contributions**

All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

**Disclosure**

SS has received grants from AstraZeneca, Dey, and Pearl Therapeutics. He has received personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Cempra, CSL Behring, Forest, GlaxoSmithKline, Merck, Pearl Therapeutics, Pulmonx, Reckitt Benckiser, Sunovion, and Theravance.

EK has served on advisory boards, speaker panels, or received travel reimbursement from Amphastar, AstraZeneca, GlaxoSmithKline, Mylan, Novartis, Oriel, Pearl Therapeutics, Sunovion, Teva, and Theravance. He has conducted multicenter clinical trials for ~40 pharmaceutical companies.

HW has received honoraria for consultancies, lectures, and travel support to attend scientific congresses from Almirall, AstraZeneca, Bayer-Chemie, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, and Takeda. His institution received investigator fees for participation in clinical trials from Almirall, AstraZeneca, Bayer Health Care, Berlin-Chemie, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Takeda. His institution received investigator fees for participation in clinical trials from Almirall, AstraZeneca, Bayer Health Care, Berlin-Chemie, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Roche, Sanofi Aventis, and Takeda.

GTF reports consulting and advisory board participation for AstraZeneca, Boehringer Ingelheim, Forest Laboratories, Novartis, Pearl Therapeutics, Sunovion, and Verona Pharma; consulting fees from Receptos; speaking engagements for AstraZeneca, Boehringer Ingelheim, Forest Laboratories, GlaxoSmithKline, Pearl Therapeutics, and Sunovion; and research grants from AstraZeneca, Boehringer Ingelheim, Forest Laboratories, GlaxoSmithKline, Novartis, Pearl Therapeutics, Sanofi, Sunovion, and Theravance Biopharma.

RMM has received consulting fees, speaker’s fees, and travel expenses from Boehringer Ingelheim and has also received compensation for participating in advisory boards for Almirall, AstraZeneca, Boehringer Ingelheim, and Novartis. Furthermore, RMM has received compensation for
participation in multicenter clinical trials in the past 5 years from several companies including Almirall, AstraZeneca, Boehringer Ingelheim, GSK, Merck Sharp & Dohme, Mundipharma, Novartis, Pearl, Roche, and Takeda.

RS, EM, DJ, and EGG are employees of AstraZeneca PLC, Barcelona, Spain.

The authors report no other conflicts of interest in this work.

References
## Supplementary materials

### Independent Ethics Committees/Institutional Review Boards and Approval Numbers

<table>
<thead>
<tr>
<th>Country</th>
<th>Name and address of Independent Ethics Committees/Institutional Review Boards consulted</th>
<th>Approval numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bulgaria</strong></td>
<td><strong>Ethics Committee for Multicenter Trials 5 Sv. Nedelya Square, Sofia 1000, Bulgaria</strong></td>
<td><strong>KH-54</strong></td>
</tr>
<tr>
<td><strong>Czech Republic</strong></td>
<td><strong>Eticka komise Oblastni nemocnice Nachod a.s. Purkynova 446, 547 69 Nachod, Czech Republic</strong>&lt;br&gt;<strong>Eticka komise Fakultní nemocnice Kralovske Vinohrady, Srobarova 50, 100 34 Praha 10 Czech Republic</strong></td>
<td><strong>S0049/2016</strong>&lt;br&gt;<strong>MEK/06/0/2016</strong></td>
</tr>
<tr>
<td><strong>Germany</strong></td>
<td><strong>Ethikkommission der Ärztekammer Hamburg, Weidestr. 122 b, 22,083 Hamburg, Germany</strong>&lt;br&gt;<strong>Ethikkommission des Landes Berlin, Landesamt für Gesundheit und Soziales, Fehrberliner Platz 1, 10,707 Berlin, Germany</strong>&lt;br&gt;<strong>Ethikkommission der Arztekommission Schleswig-Holstein, Jungfernstieg 16-Gebäude 7 23,795 Bad Segeberg, Germany</strong>&lt;br&gt;<strong>Ethikkommission an der Medizinischen Fakultät der Universität Rostock. St-Georg-Str. 108, 18,055 Rostock, Germany</strong>&lt;br&gt;<strong>Ethikkommission der Landesärztekammer Hessen, Im Vogelsgesang 3, 60,488 Frankfurt am Main, Germany</strong>&lt;br&gt;<strong>Ethikkommission bei der Sächsischen Landesärztekammer, Schützenhöhe 16, 01099 Dresden, Germany</strong>&lt;br&gt;<strong>Ethikkommission der Bayerischen Landesärztekammer Mühlbaursstraße 16, 81,677 München, Germany</strong>&lt;br&gt;<strong>Ethikkommission der Arztekommission Westfalens-Lippe und der Medizinischen Fakultät der WWU Münster, Gartenstr. 210-214 48,147 Münster, Germany</strong>&lt;br&gt;<strong>Ethikkommission zur Beurteilung medizinischer Forschung am Menschen der Ärztekammer Niedersachsen, Berliner Allee 30, 30,175 Hannover, Germany</strong></td>
<td><strong>051/16II</strong></td>
</tr>
<tr>
<td><strong>Hungary</strong></td>
<td><strong>Ethics Committee for Clinical Pharmacology of the Medical Research Council Premise: 1,054 Budapest Alkotmány u. 25; Postal address: 1051, Budapest, Arany János u. 6–8, Hungary</strong>&lt;br&gt;<strong>Balassagyarmati Orvosi Kamara Kutatásetikai Bizottság, Rákóczi út 125–127, H-2660 Balassagyarmat, Hungary</strong>&lt;br&gt;<strong>Szabolcs-Szatmár-Bereg Megyei Kórház és Egyetemi Oktatókórház, Intézeti Kutatásetikai Bizottság Szent István út 68., H-4,400 Nyíregyháza, Hungary</strong>&lt;br&gt;<strong>Szent Margit Kórház Intézeti Tudományos és Kutatásetikai Bizottság Békci út. 132., H-1032 Budapest, Hungary</strong>&lt;br&gt;<strong>Tüdőgyógyintézet Törökblázint, Etikai Bizottság Munkácsy Mihály ú. 70, H-2045 Törökblázint</strong>&lt;br&gt;<strong>Kenézy Gyula Kórház és Rendelőintézet, Intézeti Kutatásetikai Bizottság Bartók Béla út 2–26., H-4031 Debrecen, Hungary</strong>&lt;br&gt;<strong>Mohácsi Kórház Etikai Bizottság, Szepessy tér 7., H-7700 Mohács, Hungary</strong>&lt;br&gt;<strong>Komloió Egészségcentrum Intézeti Etikai Bizottság, Majáls tér 1., H-7300 Komló, Hungary</strong>&lt;br&gt;<strong>Erzsébet Gondozóház Intézményi Etikai Bizottság Légészsz u.6., H-2100 Gödöllő, Hungary</strong></td>
<td><strong>26736-0/2016-EKL</strong></td>
</tr>
<tr>
<td><strong>Israel</strong></td>
<td><strong>Helsinki Committee of Kaplan Medical Center Hagalil St, Rehovot, 7610001, Israel</strong>&lt;br&gt;<strong>Helsinki Committee (IRB) of Hadassah Medical Organization, Ein-Karem, Kiryat Hadassah, P.O Box 12000, Jerusalem 912001, Israel</strong>&lt;br&gt;<strong>Helsinki Committee of Rabin Medical Center, Beilinson Hospital, 39 Jabotinski St Petah Tikva 4941492, Israel</strong></td>
<td><strong>0047-16-KMC</strong>&lt;br&gt;<strong>0291-16-HMO</strong>&lt;br&gt;<strong>0335-15-RMC</strong></td>
</tr>
<tr>
<td><strong>Poland</strong></td>
<td><strong>Komisja Bioetyczna przy Okręgowej Izbie Lekarskiej ul. Świętojańska 7, 15–082 Białystok, Poland</strong></td>
<td><strong>31/2016/VI</strong></td>
</tr>
<tr>
<td><strong>Russia</strong></td>
<td><strong>The Ethics Council under the Ministry of Health of Russian Federation, 3, Rakhmanovskiy pereulok, Moscow, 127994, Russia</strong>&lt;br&gt;<strong>Local Independent Ethics Committee within State Budgetary Healthcare, Institution &quot;Regional Clinical Hospital #4&quot;, 376V, Pobedy prospect, Chelyabinsk, 454021, Russia</strong></td>
<td><strong>7</strong></td>
</tr>
<tr>
<td><strong>Spain</strong></td>
<td><strong>COMITÉ ÉTICO DE INVESTIGACIÓN (CEIm), Servicio Farmacología Clínica 4ª planta, Ala Norte (Puerta G), Hospital Clínico San Carlos 28.040 Madrid, Spain</strong></td>
<td><strong>16/213-R</strong></td>
</tr>
</tbody>
</table>
Sample size was calculated to provide ≥90% power to detect a statistically significant difference of 100 mL between AB/FF and AB in change from baseline in 1-hour morning post-dose FEV₁, and 65 mL between AB/FF and FF in change from baseline in morning pre-dose (trough) FEV₁, at week 24, with an SD of 230 mL based on a two-sided test at a 5% significance level. The sample size also has 90% power to show the lower bound of the two-sided 95% CI for the change from baseline in morning pre-dose (trough) FEV₁ at week 24 between AB and TIO of over -50 mL (expected difference: 0 mL; SD: 230 mL).

All lung function, health-related quality of life, and nighttime and early morning symptoms measures were analyzed by means of a mixed model for repeated measures, adjusted for covariates (pre- and post-bronchodilator FEV₁ at screening [lung function endpoints only], age, and baseline score/measure), fixed-effect factors (treatment group, sex, smoking status, visit, and treatment group-by-visit interaction), and random intercept (country).

The proportion of SGRQ and CAT responders was analyzed based on a logistic random-effect model including a random intercept to account for the variability between subjects, and adjusting for fixed factors (treatment, sex, smoking status, country, visit, and treatment group-by-visit interaction), and covariates (age and baseline).

The rate of COPD exacerbations was analyzed by negative binomial regression models, adjusting for factors (sex, baseline ICS use, baseline COPD severity, smoking status, country, prior history of exacerbation, treatment group, and offset) and covariate (age).

To control for multiplicity, endpoints were tested in a pre-specified hierarchical sequence with the order: change from baseline in 1-hour post-dose FEV₁; change from baseline in trough FEV₁; change from baseline in AUC₀−3 h FEV₁; SGRQ responder analysis. The non-inferiority between AB and TIO in change from baseline in morning pre-dose (trough) FEV₁ at week 24 will be tested at a significance level of 0.05.
Table S1 Baseline demographics and clinical characteristics (sub-study ITT population)

<table>
<thead>
<tr>
<th></th>
<th>AB/FF 400/12 µg n=120</th>
<th>AB 400 µg n=161</th>
<th>FF 12 µg n=110</th>
<th>TIO 18 µg n=172</th>
<th>Total N=563</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age, years (SD)</td>
<td>64.4 (8.5)</td>
<td>64.3 (8.1)</td>
<td>62.8 (8.7)</td>
<td>62.4 (8.3)</td>
<td>63.4 (8.4)</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>72 (60.0)</td>
<td>108 (67.1)</td>
<td>66 (60.0)</td>
<td>103 (59.9)</td>
<td>349 (62.0)</td>
</tr>
<tr>
<td>Caucasian, n (%)</td>
<td>113 (94.2)</td>
<td>150 (93.2)</td>
<td>105 (95.5)</td>
<td>162 (94.2)</td>
<td>530 (94.1)</td>
</tr>
<tr>
<td>Current smoker, n (%)</td>
<td>71 (59.2)</td>
<td>93 (57.8)</td>
<td>63 (57.3)</td>
<td>109 (63.4)</td>
<td>336 (59.7)</td>
</tr>
<tr>
<td>Smoking history, mean pack-years (SD)</td>
<td>48.3 (22.8)</td>
<td>47.0 (22.6)</td>
<td>48.0 (28.0)</td>
<td>46.4 (21.0)</td>
<td>47.3 (23.3)</td>
</tr>
<tr>
<td>Concomitant ICS use, n (%)</td>
<td>39 (32.5)</td>
<td>44 (27.3)</td>
<td>32 (29.1)</td>
<td>51 (29.7)</td>
<td>166 (29.5)</td>
</tr>
<tr>
<td>COPD severity, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>70 (58.3)</td>
<td>75 (46.6)</td>
<td>53 (48.2)</td>
<td>101 (58.7)</td>
<td>299 (53.1)</td>
</tr>
<tr>
<td>Severe</td>
<td>38 (31.7)</td>
<td>67 (41.6)</td>
<td>44 (40.0)</td>
<td>60 (34.9)</td>
<td>209 (37.1)</td>
</tr>
<tr>
<td>Very severe</td>
<td>12 (10.0)</td>
<td>19 (11.8)</td>
<td>13 (11.8)</td>
<td>11 (6.4)</td>
<td>55 (9.8)</td>
</tr>
<tr>
<td>Mean post-bronchodilator FEV₁ % predicted, mean (SD)</td>
<td>52.4 (15.5)</td>
<td>48.4 (14.7)</td>
<td>50.4 (15.2)</td>
<td>51.8 (13.5)</td>
<td>50.7 (14.6)</td>
</tr>
<tr>
<td>Bronchial reversibility, % (SD)</td>
<td>14.8 (11.8)</td>
<td>18.3 (14.5)</td>
<td>17.2 (15.4)</td>
<td>16.2 (14.1)</td>
<td>16.7 (14.1)</td>
</tr>
<tr>
<td>FEV₁, L, mean (SD)</td>
<td>1.325 (0.547)</td>
<td>1.248 (0.497)</td>
<td>1.318 (0.503)</td>
<td>1.348 (0.519)</td>
<td>1.309 (0.516)</td>
</tr>
<tr>
<td>Mean exacerbations in previous 12 months (SD)</td>
<td>0.3 (0.6)</td>
<td>0.3 (0.6)</td>
<td>0.3 (0.5)</td>
<td>0.2 (0.5)</td>
<td>0.3 (0.5)</td>
</tr>
<tr>
<td>Mean SGRQ total score (SD)</td>
<td>49.1 (16.9)</td>
<td>52.0 (16.2)</td>
<td>51.8 (17.0)</td>
<td>51.3 (16.5)</td>
<td>51.1 (16.6)</td>
</tr>
<tr>
<td>Mean CAT score (SD)</td>
<td>21.1 (5.9)</td>
<td>21.7 (6.3)</td>
<td>21.3 (6.3)</td>
<td>21.5 (6.1)</td>
<td>21.4 (6.1)</td>
</tr>
<tr>
<td>Mean NiSCI score (SD)</td>
<td>1.02 (0.69)</td>
<td>1.09 (0.73)</td>
<td>1.01 (0.72)</td>
<td>1.08 (0.76)</td>
<td>1.05 (0.73)</td>
</tr>
<tr>
<td>Mean EMSCI score (SD)</td>
<td>1.29 (0.65)</td>
<td>1.35 (0.60)</td>
<td>1.32 (0.65)</td>
<td>1.33 (0.67)</td>
<td>1.32 (0.64)</td>
</tr>
<tr>
<td>Mean E-RS score (SD)</td>
<td>12.39 (6.06)</td>
<td>13.18 (6.10)</td>
<td>12.52 (6.01)</td>
<td>12.80 (6.03)</td>
<td>12.76 (6.05)</td>
</tr>
</tbody>
</table>

Abbreviations: AB, aclidinium bromide; CAT, COPD Assessment Test; EMSCI, Early Morning Symptoms of COPD Instrument; E-RS, Evaluating-Respiratory Symptoms; FF, formoterol fumarate; ICS, inhaled corticosteroid; ITT, intent-to-treat; NiSCI, Nighttime Symptoms of COPD Instrument; SGRQ, St George’s Respiratory Questionnaire; TIO, tiotropium.

Figure S1 Change from baseline in morning pre-dose (trough) FVC (A) at week 1, and (B) week 24, ITT population.

Notes: ***p<0.001; ****p<0.0001. Data are least squares means ± standard error.

Abbreviations: AB, aclidinium bromide; FF, formoterol fumarate; ITT, intent-to-treat; TIO, tiotropium bromide.
Figure S2. Change from baseline in normalized $\text{AUC}_{0-3/3}$ FVC (A) on day 1 and (B) at week 24, ITT population.
Notes: *$\text{p} < 0.05$; **$\text{p} < 0.01$; ***$\text{p} < 0.001$. Data are least squares means ± standard error.
Abbreviations: AB, aclidinium bromide; AUC, area under the curve; FF, formoterol fumarate; ITT, intent-to-treat; TIO, tiotropium bromide.

Figure S3 (Continued)
Figure S3 Change from baseline in normalized (A and B) AUC\textsubscript{0-12/12 h}, (C and D) AUC\textsubscript{12-24/12 h}, and (E and F) AUC\textsubscript{0-24/24 h} FVC at day 1 and week 24, sub-study ITT population.

Notes: *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. Data are least squares means ± standard error.

Abbreviations: AB, aclidinium bromide; AUC, area under the curve; FF, formoterol fumarate; ITT, intent-to-treat; TIO, tiotropium bromide.